Inhibrx (NASDAQ:INBX), a biotechnology company, is dedicated to the discovery, development, and commercialization of novel therapeutics for the treatment of cancer, infectious diseases, and inflammatory conditions. This commitment is underpinned by its versatile platform and a broad pipeline, including lead programs like INBRX-101 for AATD and INBRX-109 for chondrosarcoma. With a focused approach to leveraging its proprietary technologies, Inhibrx aims to bring innovative solutions to areas of high unmet medical need. The company’s objective centers on advancing these promising therapeutic candidates through clinical trials to ultimately improve patient outcomes across various diseases.